• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1276474 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type9 y' I$ Y& c3 S0 h4 ?5 Q
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 $ C" y  i& E. M+ r; l0 W
+ Author Affiliations
% u! r( n$ G) N- I3 @3 P( W
. y! Y. m1 N  y5 G/ U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) x. ?' O& k. O  q3 N
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' y& k" J6 \. |/ T/ D1 Q$ X3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan   s/ _) I' J* V# x6 E
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ! r1 B- T! g, g$ c
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 1 ^% L9 s- j+ X
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ) U: @/ P7 F8 `6 U
7Kinki University School of Medicine, Osaka 589-8511, Japan : ?$ C# i) u( k' d6 m
8Izumi Municipal Hospital, Osaka 594-0071, Japan
) I+ r7 r. ?2 t* t( x% j' a$ ~9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan ( k  S$ a. |! y4 R! B
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp . l" H5 p* e- i& X0 h% e, b2 G+ n
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. % x- d  d! ?. [' ]; z, R; D0 S3 f

( R& a, J  [. {7 |
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type " A* F; O, A3 n8 r9 J
4 P  J, n1 D$ R& h
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 1 N  x5 B& \( w3 E- m5 S: O7 m

) t1 p8 X" h2 i* GAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  1 I9 I* ]* |* D

1 g" u: v1 c2 o% d/ o  M4 d7 xPublished online on: Thursday, December 1, 2011
$ G/ l5 l! N0 @2 Z( a% l. Q
. X$ K' l8 D/ ~6 M* h7 {Doi: 10.3892/ol.2011.507 4 J, R1 O* L  x  R; \

1 @5 m+ [" Y4 h" o, fPages: 405-410 ' q" M6 d! y" G  B7 y& w, ]* E
1 [0 V- x# x5 k7 L' M) y" s3 q: M
Abstract:* ]3 X! w) d; o! G. M
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
- d$ Z. x: P1 |3 {. Q( _ + b( ?/ `7 o( `8 H& W2 `0 r
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population: i+ X. E, O; M# F1 U; \5 O
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 " m: @" Q$ O  c5 k
+ Author Affiliations. [! K+ Q! Y, H. Q+ f4 y
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
6 n' e* [/ L, t& T) o/ L$ R* P2Department of Thoracic Surgery, Kyoto University, Kyoto 8 O3 q# c5 N- ]" I
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan & \; U: K* k/ {
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp ( q: G% q% @, e) |% C7 e2 w
Received September 3, 2010.
. k* {! H! [0 ]! ]* t) iRevision received November 11, 2010.
: r& n* R6 n- L8 CAccepted November 17, 2010. % h, J# v+ O$ T1 {* a! s
Abstract
& \( L  s: S- ~" Y2 r  rBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
8 Y0 U+ l. y; R7 y! b2 m& C# NPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. ) D" K7 b8 ~2 }3 ~7 p
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. % Q" Q; J6 }+ X# F
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
8 `0 s0 b( t2 n9 M6 U0 s
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
6 {. Q% Y7 X# Q+ O! ^; R5 Y今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?. w9 ^7 D3 H8 l* X
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
+ C- t/ V9 I, [4 y! g2 rhttp://clinicaltrials.gov/ct2/show/NCT01523587# O8 B* d3 ]6 j, b: B( L! ]  ?
$ S( u9 g5 W6 b: h/ d
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
% W- s3 v- e8 f, `- J$ i$ H+ J( yhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
* i1 ?# ^6 H, D% I- @1 O
! c$ [+ f5 @0 E从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
) D8 S2 _1 _2 z1 ]/ h# }  T& [8 K至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
5 |" U% K; ~7 g
没有副作用是第一追求,效果显著是第二追求。7 X( l9 Y7 v6 m* V3 z
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表